<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21703">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01908712</url>
  </required_header>
  <id_info>
    <org_study_id>rhLAMAN-07</org_study_id>
    <secondary_id>2013-000336-97</secondary_id>
    <nct_id>NCT01908712</nct_id>
  </id_info>
  <brief_title>Lamazym Aftercare Study FR</brief_title>
  <acronym>rhLAMAN-07</acronym>
  <official_title>A Single-center, Un-controlled, Open-labeled Trial of the Long-term Safety of Lamazym Aftercare Treatment of Subjects With Alpha-Mannosidosis Whom Previously Participated in Lamazym Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zymenex A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zymenex A/S</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this trial is to provide aftercare treatment with Lamazym and to
      evaluate the safety of repeated Lamazym i.v. treatment of subjects with alpha-Mannosidosis
      whom previously participated in Lamazym-trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial provide aftercare treatment with Lamazym to French patients.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in Adverse events</measure>
    <time_frame>3 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AE documented at every visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Lamazym antibodies</measure>
    <time_frame>3 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AB measured every 12th week</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progress from baseline in number of steps climbed in 3 minutes</measure>
    <time_frame>1 year, 2 year and 3 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progress from baseline in equivalent age</measure>
    <time_frame>1 year, 2 year and 3 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progress from baseline in Forced Vital Capacity</measure>
    <time_frame>1 year, 2 year and 3 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progress from baseline in distance walked in 6 minutes</measure>
    <time_frame>1 year, 2 year and 3 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Alpha-Mannosidosis</condition>
  <arm_group>
    <arm_group_label>Lamazym</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg Lamazym/kg body weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamazym</intervention_name>
    <description>ERT, i.v. infusions weekly</description>
    <arm_group_label>Lamazym</arm_group_label>
    <other_name>rhLAMAN</other_name>
    <other_name>recombinant human alpha-mannosidase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the subject must have participated in previous Lamazym-trials: phase 2b:
             2011-004355-40 or phase 3: 2012-000979-17

          -  Subject or subjects legally authorized guardian(s) must provide signed, informed
             consent prior to performing any trial-related activities

          -  The subject and his/her guardian(s) must have the ability to comply with the protocol

        Exclusion Criteria:

          -  Presence of known clinically significant cardiovascular, hepatic, pulmonary, or renal
             disease or other medical conditions that, in the opinion of the Investigator, would
             preclude participation in the trial

          -  Any other medical condition or serious intercurrent illness, or extenuating
             circumstances that, in the opinion of the Investigator, would preclude participation
             in the trial

          -  Pregnancy. Pregnant woman is excluded. Before start fot he treatment the
             investigators will for women of childbearing potential perform a pregnancy test and
             decide whether or not there is a need for contraception

          -  Psychosis; any psychotic disease, also in remission, is an exclusion criteria

          -  Planned major surgery that, in the opinion of the Investigator, would preclude
             participation in the trial

          -  Adult patients who, in the opinion of the Investigator, would be unable to give
             consent, and who does not have any legal protection or guardianship

          -  total IgE &gt; 800 IU/mL

          -  Known allergy to the IMP or any excipients (Sodium-Phosphate, Glycine, Mannitol)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan M Lund, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Copenhagen University Hospital, Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Femme Mére Enfant - CHU de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>F-69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.google.dk/url?sa=t&amp;rct=j&amp;q=line%20borgwardt&amp;source=web&amp;cd=1&amp;cad=rja&amp;sqi=2&amp;ved=0CCsQtwIwAA&amp;url=http%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DZGgqK7oJQFQ&amp;ei=4TG4UejWD8SSO7TqgbAI&amp;usg=AFQjCNG4azVFYvyGp-yNBeoP4tG6YQQ1Tw&amp;bvm=bv.47810305,d.ZWU</url>
    <description>12th international symposium on MPS and related diseases</description>
  </link>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 23, 2013</lastchanged_date>
  <firstreceived_date>July 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alpha-Mannosidosis</mesh_term>
    <mesh_term>Mannosidase Deficiency Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
